The use of peripheral CD3
Humans
Carcinoma, Hepatocellular
/ immunology
Liver Neoplasms
/ immunology
Male
Female
Retrospective Studies
Middle Aged
Immune Checkpoint Inhibitors
/ therapeutic use
Immunotherapy
/ methods
Aged
Prognosis
CD3 Complex
/ metabolism
T-Lymphocyte Subsets
/ immunology
Adult
Receptors, Antigen, T-Cell, gamma-delta
/ metabolism
Hepatocellular carcinoma
Immunotherapy
T lymphocyte subsets
Γδ T cell
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
25 Jul 2024
25 Jul 2024
Historique:
received:
26
05
2024
accepted:
15
07
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
25
7
2024
Statut:
epublish
Résumé
Currently, there is a lack of effective indicators for predicting the efficacy of immunotherapy in patients with advanced hepatocellular carcinoma (HCC). This study aimed to investigate the expression and prognostic value of peripheral T lymphocyte subsets in advanced HCC. Patients with advanced HCC who were treated with immune checkpoint inhibitors (ICIs) from December 2021 to December 2023 were included in the study. Flow cytometry was used to detect lymphocyte subsets before treatment. The patients were divided into disease control (DC) and nondisease control (nDC) groups based on treatment efficacy. Relationships between the clinical characteristics/peripheral T lymphocytes and immunotherapy efficacy were analyzed. The effectiveness of peripheral T lymphocyte subsets in predicting immunotherapy efficacy for patients with advanced HCC was analyzed using receiver operating characteristic (ROC) curves. A total of 40 eligible patients were included in this study. Non-DC was significantly associated with higher albumin-bilirubin (ALBI) scores. The percentages of γδ The calculation of the ALBI score and determination of the percentages CD3
Sections du résumé
BACKGROUND
BACKGROUND
Currently, there is a lack of effective indicators for predicting the efficacy of immunotherapy in patients with advanced hepatocellular carcinoma (HCC). This study aimed to investigate the expression and prognostic value of peripheral T lymphocyte subsets in advanced HCC.
METHODS
METHODS
Patients with advanced HCC who were treated with immune checkpoint inhibitors (ICIs) from December 2021 to December 2023 were included in the study. Flow cytometry was used to detect lymphocyte subsets before treatment. The patients were divided into disease control (DC) and nondisease control (nDC) groups based on treatment efficacy. Relationships between the clinical characteristics/peripheral T lymphocytes and immunotherapy efficacy were analyzed. The effectiveness of peripheral T lymphocyte subsets in predicting immunotherapy efficacy for patients with advanced HCC was analyzed using receiver operating characteristic (ROC) curves.
RESULTS
RESULTS
A total of 40 eligible patients were included in this study. Non-DC was significantly associated with higher albumin-bilirubin (ALBI) scores. The percentages of γδ
CONCLUSIONS
CONCLUSIONS
The calculation of the ALBI score and determination of the percentages CD3
Identifiants
pubmed: 39052085
doi: 10.1007/s00432-024-05896-y
pii: 10.1007/s00432-024-05896-y
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
CD3 Complex
0
Receptors, Antigen, T-Cell, gamma-delta
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
365Subventions
Organisme : Clinical research project of Air Force Medical Center
ID : 2021LC013
Informations de copyright
© 2024. The Author(s).
Références
Abdelrahman DI, Elhasadi I, Anbaig A et al (2024) Immunohistochemical expression of Immune checkpoints; CTLA-4, LAG3, and TIM-3 in Cancer cells and tumor-infiltrating lymphocytes (TILs) in colorectal carcinoma. Appl Immunohistochem Mol Morphology 32:71–83. https://doi.org/10.1097/PAI.0000000000001181
doi: 10.1097/PAI.0000000000001181
Allemani C, Matsuda T, Di Carlo V et al (2018) Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391:1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3
doi: 10.1016/S0140-6736(17)33326-3
pubmed: 29395269
pmcid: 5879496
Du Y, Peng Q, Cheng D et al (2022) Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement with IL-17A-producing γδ T cells. Nat Commun 13:231. https://doi.org/10.1038/s41467-021-27936-8
doi: 10.1038/s41467-021-27936-8
pubmed: 35017553
pmcid: 8752682
Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382:1894–1905. https://doi.org/10.1056/NEJMoa1915745
doi: 10.1056/NEJMoa1915745
pubmed: 32402160
Giovannini C, Suzzi F, Tovoli F et al (2023) Low-baseline PD1 + granulocytes predict responses to Atezolizumab–bevacizumab in Hepatocellular Carcinoma. Cancers 15:1661. https://doi.org/10.3390/cancers15061661
doi: 10.3390/cancers15061661
pubmed: 36980547
pmcid: 10045974
Hong JY, Cho HJ, Sa JK et al (2022) Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. Genome Med 14:1. https://doi.org/10.1186/s13073-021-00995-8
doi: 10.1186/s13073-021-00995-8
pubmed: 34986867
pmcid: 8734300
Hu Y, Hu Q, Li Y et al (2023) γδ T cells: origin and fate, subsets, diseases and immunotherapy. Sig Transduct Target Ther 8:434. https://doi.org/10.1038/s41392-023-01653-8
doi: 10.1038/s41392-023-01653-8
Johnson PJ, Berhane S, Kagebayashi C et al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 33:550–558. https://doi.org/10.1200/JCO.2014.57.9151
doi: 10.1200/JCO.2014.57.9151
pubmed: 25512453
Kabelitz D, Serrano R, Kouakanou L et al (2020) Cancer immunotherapy with γδ T cells: many paths ahead of us. Cell Mol Immunol 17:925–939. https://doi.org/10.1038/s41423-020-0504-x
doi: 10.1038/s41423-020-0504-x
pubmed: 32699351
pmcid: 7609273
Kelley RK, Rimassa L, Cheng A-L et al (2022) Cabozantinib plus Atezolizumab versus Sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 23:995–1008. https://doi.org/10.1016/S1470-2045(22)00326-6
doi: 10.1016/S1470-2045(22)00326-6
pubmed: 35798016
Lee D, Rosenthal CJ, Penn NE et al (2022) Human γδ T cell subsets and their clinical applications for Cancer Immunotherapy. Cancers 14:3005. https://doi.org/10.3390/cancers14123005
doi: 10.3390/cancers14123005
pubmed: 35740670
pmcid: 9221220
Liu B, He X, Wang Y et al (2022) Bibliometric Analysis of γδ T Cells as Immune regulators in Cancer Prognosis. Front Immunol 13:874640. https://doi.org/10.3389/fimmu.2022.874640
doi: 10.3389/fimmu.2022.874640
pubmed: 35493488
pmcid: 9048597
Liu H, Gan X-M, Sun J-M et al (2024) Transcatheter arterial chemoembolisation combined with lenvatinib and cabozantinib in the treatment of advanced hepatocellular carcinoma. Int Immunopharmacol 130:111510. https://doi.org/10.1016/j.intimp.2024.111510
doi: 10.1016/j.intimp.2024.111510
pubmed: 38422766
Mamedov MR, Vedova S, Freimer JW et al (2023) CRISPR screens decode cancer cell pathways that trigger γδ T cell detection. Nature 621:188–195. https://doi.org/10.1038/s41586-023-06482-x
doi: 10.1038/s41586-023-06482-x
pubmed: 37648854
pmcid: 11003766
Ni C, Fang Q-Q, Chen W-Z et al (2020) Breast cancer-derived exosomes transmit lncRNA SNHG16 to induce CD73 + γδ1 Treg cells. Sig Transduct Target Ther 5:41. https://doi.org/10.1038/s41392-020-0129-7
doi: 10.1038/s41392-020-0129-7
Öcal O, Kimm MA, Hoang TPT et al (2024) Predictive value of platelet-to-lymphocyte and neutrophil-to-lymphocyte ratio in HCC treated with sorafenib and radioembolization. JHEP Rep 6:100995. https://doi.org/10.1016/j.jhepr.2023.100995
doi: 10.1016/j.jhepr.2023.100995
pubmed: 38440069
Park JH, Kim H-J, Kim CW et al (2021) Tumor hypoxia represses γδ T cell-mediated antitumor immunity against brain tumors. Nat Immunol 22:336–346. https://doi.org/10.1038/s41590-020-00860-7
doi: 10.1038/s41590-020-00860-7
pubmed: 33574616
Rancan C, Arias-Badia M, Dogra P et al (2023) Exhausted intratumoral Vδ2 – γδ T cells in human kidney cancer retain effector function. Nat Immunol 24:612–624. https://doi.org/10.1038/s41590-023-01448-7
doi: 10.1038/s41590-023-01448-7
pubmed: 36928415
pmcid: 10063448
Ren Z, Xu J, Bai Y et al (2021) Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. Lancet Oncol 22:977–990. https://doi.org/10.1016/S1470-2045(21)00252-7
doi: 10.1016/S1470-2045(21)00252-7
pubmed: 34143971
Sangro B, Melero I, Wadhawan S et al (2020) Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol 73:1460–1469. https://doi.org/10.1016/j.jhep.2020.07.026
doi: 10.1016/j.jhep.2020.07.026
pubmed: 32710922
pmcid: 7751218
Silva-Santos B, Mensurado S (2023) γδ T cells maintain sensitivity to immunotherapy in MHC-I-deficient tumors. Nat Immunol 24:387–388. https://doi.org/10.1038/s41590-023-01429-w
doi: 10.1038/s41590-023-01429-w
pubmed: 36781987
Singal AG, El-Serag HB (2015) Hepatocellular Carcinoma from Epidemiology to Prevention: translating knowledge into practice. Clin Gastroenterol Hepatol 13:2140–2151. https://doi.org/10.1016/j.cgh.2015.08.014
doi: 10.1016/j.cgh.2015.08.014
pubmed: 26284591
pmcid: 4618036
Statements & Declarations
Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660
doi: 10.3322/caac.21660
pubmed: 33538338
Tian Y-B, Niu H, Xu F et al (2024) ALBI score combined with FIB-4 index to predict post-hepatectomy liver failure in patients with hepatocellular carcinoma. Sci Rep 14:8034. https://doi.org/10.1038/s41598-024-58205-5
doi: 10.1038/s41598-024-58205-5
pubmed: 38580647
pmcid: 10997654
Willcox CR, Mohammed F, Willcox BE (2020) The distinct MHC-unrestricted immunobiology of innate‐like and adaptive‐like human γδ T cell subsets—Nature’s CAR‐T cells. Immunol Rev 298:25–46. https://doi.org/10.1111/imr.12928
doi: 10.1111/imr.12928
pubmed: 33084045
Wonglhow J, Sunpaweravong P, Sathitruangsak C, Dechaphunkul A (2024) The performance of a Survival Nomogram and Albumin-Bilirubin Grade as Prognostic Tools in Advanced Hepatocellular Carcinoma treated with FOLFOX4. J Pers Med 14:403. https://doi.org/10.3390/jpm14040403
doi: 10.3390/jpm14040403
pubmed: 38673030
pmcid: 11051573
Yin K-L, Chu K-J, Li M et al (2024) Immune Regulatory Networks and Therapy of γδ T cells in Liver Cancer: recent trends and advancements. J Clin Transl Hepatol 000:000–000. https://doi.org/10.14218/JCTH.2023.00355
doi: 10.14218/JCTH.2023.00355
Yoshino Y, Suzuki G, Shiomi H et al (2024) Albumin-bilirubin score is a useful predictor of worsening liver reserve after stereotactic body radiation therapy in elderly Japanese patients with hepatocellular carcinoma. J Radiat Res 65:244–250. https://doi.org/10.1093/jrr/rrae006
doi: 10.1093/jrr/rrae006
pubmed: 38415344
pmcid: 10959440
Zhang J, Ren Z, Hu Y et al (2024) High HPK1 + PD-1 + TIM-3 + CD8 + T cells infiltration predicts poor prognosis to immunotherapy in NSCLC patients. Int Immunopharmacol 127:111363. https://doi.org/10.1016/j.intimp.2023.111363
doi: 10.1016/j.intimp.2023.111363
pubmed: 38101218